MENU
MAY 02, 2017 8:00 AM PDT

Counteracting tumor evasion of antibody immunity, free webinar and Q&A session

Sponsored by: Abcam
Speaker
  • Professor of Molecular Medicine, Robert A. Welch Distinguished University Chair in Chemistry; Director, Texas Therapeutics Institute University of Texas Health Science Center at Houston
    Biography
      Dr. Zhiqiang An is Professor of Molecular Medicine, the Robert A. Welch Distinguished University Chair in Chemistry, and Director of the Texas Therapeutics Institute at the University of Texas Health Science Center at Houston. His laboratory focuses on cancer antibody drug resistance mechanisms, biomarkers for cancer therapeutic antibodies, and antibody drug discovery targeting cancer and infectious diseases. Dr An also directs the Therapeutic Monoclonal Antibody Lead Optimization and Development Core Facility funded by the Cancer Prevention and Research Institute of Texas (CPRIT).

      Previously, Dr. An served as Chief Scientific Officer at Epitomics, Inc. and was Director of Biologics Research at Merck Research Laboratories. He is a fellow of Society for Industrial Microbiology and Biotechnology, and is well published in the field of antibody drug discovery, including the award-winning book "Therapeutic Monoclonal Antibodies: from Bench to Clinic".

      Dr An started his biotech career at Millennium Pharmaceuticals. He received his Ph.D. degree from the University of Kentucky and his postdoctoral training at the University of Wisconsin-Madison.

    Abstract

    DATE: May 2, 2017
    TIME: 8:00am PT, 11:00am ET, 4:00pm GMT, 5:00pm CET

    The natural immune responses that patients develop to their own tumors, as well as therapeutic regimens employing the latest anti-cancer monoclonal antibodies, would reasonably be expected to suppress tumor growth. Yet, a perplexing resistance to both is widespread. The ineffectiveness of the immune system to prevail in these situations suggests that cancers possess tactics to evade antibodies that could otherwise eradicate them. 

    With a clinical context in mind, we observed that tumor-associated protein-degrading enzymes can diminish, and in some cases negate, cell killing functions by inducing a single clip in a small part of the antibody structure. The structural modification is so subtle that it had not been previously recognized and would not have been anticipated to so profoundly impair the antibody. To be able to visualize and establish if such cleavage occurred in cancer, we had to develop innovative antibodies for that exact purpose. 

    The new antibodies readily enabled the visualization of antibody damage when incubated with cancer cells in the laboratory or within tumor tissues obtained from animals or human patients - more importantly - the same antibody tools possessed the additional and remarkable property of restoring the lost functions to the damaged antibodies. The “rescue” of lost function suggested that this could be exploited as a therapy in cases where tumors cause antibody damage in order to evade our immune system. This novel therapeutic strategy represents a potentially new direction in cancer immunotherapy.

    This webinar will review:

    • A minor proteolytic cleavage at IgG hinge greatly impairs the effector functions of anticancer antibodies
    • Proteolytic hinge cleavage of IgGs as a mechanism of tumor evasion of antibody-based immunity
    • The potential of “rescue” of lost IgG Fc function as a novel therapeutic strategy for cancer

    Learning Objectives:

    • Review mechanisms of tumor cells used to evade interaction from anti-cancer antibodies 
    • Learn how antibody technology can be used to develop antibodies capable of visualizing subtle, specific modifications
    • Learn about a potential novel cancer therapeutic method of ‘’restoring’’ antibodies damaged by tumor-associated protein-degrading enzymes

    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    MAY 02, 2017 8:00 AM PDT

    Counteracting tumor evasion of antibody immunity, free webinar and Q&A session

    Sponsored by: Abcam

    Specialty

    Cancer Research

    Immunology

    Biotechnology

    Molecular Biology

    Cell Biology

    Cancer Therapeutics

    Biomarkers

    Cancer Diagnostics

    Clinical Diagnostics

    Clinical Research

    Molecular Diagnostics

    Oncology

    Infectious Disease

    Antibodies

    Genetics

    Geography

    North America64%

    Asia14%

    Europe11%

    South America5%

    Africa3%

    Oceania1%

    Registration Source

    Website Visitors100%

    Job Title

    Executive16%

    Research Scientist14%

    Scientist13%

    Student11%

    Medical Doctor/Specialist8%

    Medical Laboratory Technician8%

    Facility/Department Manager7%

    Lab Management6%

    Educator/Faculty5%

    Clinical Laboratory Scientist3%

    Post Doc3%

    Biologist2%

    Marketing/Sales1%

    Chemist1%

    Organization

    Biotech Company12%

    Academic Institution10%

    Hospital8%

    Clinical Laboratory5%

    Pharmaceutical Company4%

    Life Science Company3%

    Research Institute2%

    Consultant2%

    Medical School2%

    Ambulatory Care2%

    Medical Center2%

    Contract Research Organization (Cro)1%

    Non-Profit Organization1%

    Industrial Company1%

    Other1%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more